Clinical Trial Update: Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

View source ↗

Summary

Pozelimab has been approved for marketing for CD55-Deficient Protein-Losing Enteropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd55-deficient Protein-losing Enteropathy

Drugs mentioned

• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: CD55-Deficient Protein-Losing Enteropathy | Status: APPROVED_FOR_MARKETING